Dermatomyositis as the first manifestation of paraneoplastic syndrome, in bladder cancer
Main Article Content
Keywords
Dermatomyositis, Paraneoplastic Syndromes, Urinary Bladder Neoplasms
Abstract
Dermatomyositis (DM) is an idiopathic inflammatory myopathy, characterized by an inflammatory infiltrate affecting the skeletal muscle and skin with its characteristic skin lesions. Dermatomyositis is strongly associated with several types of neoplasia approximately 13-42%. When the symptoms of Dermatomyositis are associated with malignancy, the condition is known as paraneoplastic syndrome that represents the clinical manifestations of the indirect effects produced by tumor metabolites and other products. Paraneoplastic dermatomyositis secondary to transitional cell carcinoma of the bladder has been observed very rarely and without data of association with squamous cell cancer. We present the case of a 59-year-old male patient with a history of BPH, who started with symptoms of progressive muscle weakness, malar erythema, gottron papules, and due to clinical features CPK was performed, resulting in a high-resolution biopsy. muscle to confirm diagnosis of DM. Subsequently, cystoscopy and bladder lavage plus biopsy were performed, confirming the diagnosis of bladder cancer. It is considered that malignancy is associated with dermatomyositis as a paraneoplastic syndrome, therefore, the importance of screening for cancer in patients who debut with dermatomyositis is confirmed.
References
2. Fitzpatrick J, Wallace WA, Lang S, Aboumarzouk OM Windsor P, Nabi G. Recurrent dermatomyositis manifesting as a sign of recurrent transitional cell carcinoma of urinary bladder: Long-term survival. Urol Ann. julio de 2014;6(3):264-6.
3. Iaccarino L, Ghirardello A, Bettio S, Zen M, Gatto M, Punzi L, et al. The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun. marzo de 2014;48-49:122-7.
4. Leatham H, Schadt C, Chisolm S, Fretwell D, Chung L, Callen JP, et al. Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts. Medicine (Baltimore). enero de 2018;97(2):e9639.
5. Requena C, Alfaro A, Traves V, Nagore E, Llombart B, Serra C, et al. Dermatomiositis paraneoplásica: estudio de 12 casos. Actas Dermo-Sifiliográficas. 2014;105(7):675–682.
6. Kuo C-F, See L-C, Yu K-H, Chou I-J, Chang H-C, Chiou M-J, et al. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol. diciembre de 2011;165(6):1273-9.
7. López-Riverol O, Camacho-Limas CP, Gerson-Cwilich R. Síndromes paraneoplásicos. Diagnóstico y tratamiento. Rev Hosp Juárez México. 2016;83(1-2):31–40.
8. Teoh JW, Yunus RM, Hassan F, Ghazali N, Abidin ZAZ. Nasopharyngeal carcinoma in dermatomyositis patients: A 10-year retrospective review in Hospital Selayang, Malaysia. Rep Pract Oncol Radiother J Gt Cancer Cent Poznan Pol Soc Radiat Oncol. septiembre de 2014;19(5):332-6.
9. Fitzpatrick J, Wallace WA, Lang S, Aboumarzouk OM, Windsor P, Nabi G. Recurrent dermatomyositis manifesting as a sign of recurrent transitional cell carcinoma of urinary bladder: Long-term survival. Urol Ann. julio de 2014;6(3):264-6.
10. González Resina R, Sánchez Bernal ML, Pérez Espejo MP, Rodríguez Corchero FJ, Argüelles Salido E, Campoy Martínez P. Carcinoma epidermoide vesical: Revisión de nuestra serie. Arch Esp Urol Ed Impresa. 2006;59(8):785–790.
11. Fernández E. Dermatomiositis (Informe del primer caso en Honduras). Dermatologia. Rev Med Hond. (34): 237- 241. Disponible en: http://ns.bvs.hn/RMH/pdf/1966/pdf/Vol34-4-1966-4.pdf
12. Kaminsky A, Caceres M, Charas V, Diaz M. Dermatomiositis. Med cutan Iber Lat Am. 2002; 30 (2): 39- 52.
13. Noda T, Iijima M, Noda S, Maeshima S, Nakanishi H, Kimura S, et al. Gene Expression Profile of Inflammatory Myopathy with Malignancy is Similar to that of Dermatomyositis rather than Polymyositis. Intern Med Tokyo Jpn. 2016;55(18):2571-80.
14. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 1 de marzo de 2017;71(3):447-61.
15. Udkoff J, Cohen PR. Amyopathic Dermatomyositis: A Concise Review of Clinical Manifestations and Associated Malignancies. Am J Clin Dermatol. octubre de 2016;17(5):509-18.